What question did this study set out to answer?

To evaluate the efficacy of immunosuppressive therapy in patients diagnosed with virus-negative inflammatory cardiomyopathy.

June 25, 2009European Heart JournalOpen Access

Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study

View Full Paper

Ask AI

Bookmark

Why the study?

Does immunosuppressive therapy improve outcomes in patients with virus-negative inflammatory cardiomyopathy?

Population

Patients with virus-negative inflammatory cardiomyopathy

Design

RCT, Randomized

Authors

AFAndrea FrustaciHeart Failure & Transplant MRMartina RussoSapienza University of Rome CCCristina ChimentiHeart Failure & Transplant

Discussion

Member takes

Implication

Supports immunosuppression as standard in virus-negative inflammatory cardiomyopathy; confirms RCT efficacy while highlighting 12% non-response for further study.

Key Points

To evaluate the efficacy of immunosuppressive therapy in patients diagnosed with virus-negative inflammatory cardiomyopathy.
Conducted a randomized study (the TIMIC study) evaluating immunosuppressive therapy.
Assessed clinical response in patients with confirmed virus-negative inflammatory cardiomyopathy.
Immunosuppression confirmed therapeutic efficacy in treating virus-negative inflammatory cardiomyopathy.
Treatment failure occurred in 12% of cases, indicating potential unscreened viral infection or alternate pathways of tissue injury.

Structured PICO

Does immunosuppressive therapy improve outcomes in patients with virus-negative inflammatory cardiomyopathy?

Population

Patients with virus-negative inflammatory cardiomyopathy

Intervention

Immunosuppressive therapy

Immunosuppressive therapy is efficacious in treating virus-negative inflammatory cardiomyopathy, although a small subset of patients may not respond.

Cite This Study

Frustaci et al. (2009) studied this question.

synapsesocial.com/papers/69d9ea3b0f32475823a3caa6 https://doi.org/10.1093/eurheartj/ehp249

Topics

HFrEF treatment Heart failure Myocarditis

View Full Paper

Ask AI

Bookmark

Implication

Supports immunosuppression as standard in virus-negative inflammatory cardiomyopathy; confirms RCT efficacy while highlighting 12% non-response for further study.

Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider